Carregant...
The OlympiAD trial: who won the gold?
OlympiAD was a phase 3 randomized controlled trial of a PARP inhibitor olaparib for metastatic HER2 negative breast cancer patients harboring a BRCA mutation. Although the OlympiAD trial met its primary endpoint, there are concerns regarding whether olaparib truly improves meaningful outcomes for th...
Guardat en:
| Publicat a: | Ecancermedicalscience |
|---|---|
| Autor principal: | |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Cancer Intelligence
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5739869/ https://ncbi.nlm.nih.gov/pubmed/29290761 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3332/ecancer.2017.ed75 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|